Biotech Values

[DewDiligence]

SGP’s HCV franchise is generating sales at a $1.3B annual rate despite its consisting of:

1. A second-best product in its class (Peg-Intron);
2. An obsolete product (Intron-A); and
3. A product whose patent has run out (Rebetol).

They must have some good sales reps.